65,437 trials
Healthy
Primary: AUC0-tz of Empagliflozin in Plasma — 2190; 2210 nmol*h/L — p=<0.0001
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
Chronic Rhinosinusitis
Primary: Quality of Life in Chronic Rhinosinusitis Patients — 23; 21 Units on a scale
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score at Week 8 (Treatment 1 and 2 Versus [vs.] Placebo) — 2.51; 2.53; 2.54; -1.57 Score on scale — p=<0.0001
Genital Herpes
Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With Suppressive Acyclovir…
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 5; 5; 6; 3 Participants
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin — 2630…
Breast Cancer · Depression · Fatigue
Primary: Retention — 82; 89 percentage of participants — p=.53
Metastatic Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of TAK-117 — 150; 900; 900; NA mg
Leishmaniasis
Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants
Q Fever
Primary: The Adverse Reaction and Occupational Illness Endpoint Measurements in This Q Fever NDBR 105 Vaccine Study Will be Evaluated for All Intent-to-treat Volunteers. — 10…
Multiple Myeloma
Primary: Number of Participants With Adverse Events — 19; 3; 3; 3 participants
Diffuse, Large B-Cell, Lymphoma · Lymphoma, Low-Grade · T-Cell Lymphoma
Primary: Peripheral Blood All-cell Donor Chimerism — 95 percentage of donor-derived elements
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants